Xo1: Index Ventures exits X01
According to a blog post on its site, Index Ventures has sold X01 Ltd to Janssen Pharmaceuticals Inc, a Johnson and Johnson subsidiary. No financial terms were disclosed. X01 is a cardiovascular drug startup. To read the announcement, visit here.
Read full article »
XO1 is a virtual biopharmaceutical firm that develops ichorcumab an anti-thrombin antibody that delivers anticoagulation without bleeding.
Read more